

****Published August 2023****

Vaccines/mRNA Strategic Pipeline Review (CAT: VAMV084)

Product Name	:	Vaccines/mRNA Strategic Pipeline Review
Description	:	Global vaccine R&D analysis – Industry only
Contents	:	Executive presentation (>120 slides.pdf) + 1 x MS-Excel Workbook (>1750 trials, >266 companies, 90 pathogens)
Therapeutic Area	:	All vaccines (general)
Publication date	:	August 2023
Catalogue No	:	VAMV084

Background

Analysis of the current and historical vaccine **research and development (R&D) pipeline** is a critical component of any organisation's competitive intelligence effort. This exercise can inform both internal & external decision makers and input into many processes, including strategic portfolio management, business development and licensing, R&D prioritization and corporate development/investment. Key challenges with the analysis are that, not only is the vaccine pipeline dynamic, but a historical view requires skilled judgement during curation, especially when assigning new fields which can produce meaningful outputs.

This **Q3 2023 Vaccines/mRNA Strategic Pipeline Review (industry only)** contains analysis of **>1750** total clinical trials operated by **>266** companies and investigates current and historical vaccine trial activity by inserting a range of new fields including vaccine type/production system/adjuvant* including mRNA landscape analysis, infectious diseases, chronic conditions or cancer, pathogen/condition (~90 included), market segment, study duration and company size (Small, Medium and Large) and more. Using the MS-Excel workbook provided, a range of tabular and graphical outputs help visualize competitive activity [current/past] and investment in various segments/pathogens relative to each other and the academic sector. These outputs form the basis of a gap analysis or heatmap that could guide future investment especially with regard to new nucleic-based approaches.

A **new mRNA vaccine landscape focus** section is now included and newly emerging seasonal influenza and RSV programs including mRNA-1010, mRNA-1020/30, mRNA-1073, mRNA-1345, mRNA-1230, mRNA-1045, mRNA-1365 (ModernaTX), PF-07252220, PF07852352, PF-07941314 (Pfizer), GSK4382276A (GSK), and SP0273 MRT5400, MRT5401, CL-0059/CL-0137 (Sanofi). Companies possessing mRNA technologies within the COVID-19 space are considered with an indication of the level of Self-amplifying technologies[SAM] and other novel formats. New entrants such as **AstraZeneca/Cansino** and an analysis of mRNA programs focused on non-ID areas e.g. oncology is now included.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to vaccine research & development activity. Source materials used are global clinical trial registries, literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of vaccines been used as a reference.

PRODUCT CONTENTS:

Published August 2023 (CAT No: VAMV084)

****This product is a [summary presentation \(.pdf\)](#), and a [MS Excel Workbook \(.xls\)](#)

Contents – Summary presentation (.pdf)¹

Contents
Author's notes
Executive summary
Methodology 1)
Methodology 2)
Pathogens and conditions identified
Market segment definitions
Number of vaccine clinical trials identified
Number of vaccine clinical trials: cancer vs non cancer
Number of vaccine clinical trials: activity status
Number of vaccine clinical trials: by Phase 1-4
Number of vaccine clinical trials: per pathogen condition
Number of vaccine clinical trials: per segment/activity
Number of vaccine clinical trials: per company size
Number of clinical trials per company size
Large companies involved in vaccine clinical trials
Medium companies involved in vaccine clinical trials
Small companies involved in vaccine clinical trials
Large companies: past/current clinical trials per market segment
Large companies: past/current clinical trials per pathogen/condition
Large companies: verified active programs by Phase, Q3 2022
Large companies: verified active programs by segment, Q3 2022
Large companies: verified active programs by pathogen, Q3 2022
Proprietary analysis (titles not disclosed)
Caveats and limitations of the analysis
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: >120 slides fully referenced/sourced. Available in .pdf form

Contents – MS Excel Workbook
Worksheets = >50 interconnected

¹ Full contents i.e., title per slide is proprietary and only available upon request



PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (both deliverables) - USD **\$7,995.00**/ GBP **£6,295.00**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to the final invoice total

- *indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary*

HOW TO ORDER:

To order, please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – only available upon valid request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars, or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees, and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 927049 / Fax: +44 (0) 1279 927049

E-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new monoclonals and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and “the spiral logo” are UK Registered Trademarks, 2009

